COO vs HNGE: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: COO is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. COO and HNGE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined COO and HNGE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

The Cooper Companies, headquartered in San Ramon, California and employing roughly ~15,000 people, has run on the same two-segment structure for years. CooperVision, about two thirds of revenue at ~$717.0M in the July 2026 quarter, makes soft contact lenses: daily disposables in silicone hydrogel, torics for astigmatism, multifocals for presbyopia, and MiSight 1 day, the only daily disposable lens with FDA approval to slow the progression of myopia in children. CooperSurgical, the other third at ~$349.2M, splits into fertility (IVF consumables, embryo culture media, cryostorage and genetic testing sold to fertility clinics) and an office and surgical line of devices sold into OB/GYN practices. The fiscal year ends October 31, so results labelled fiscal 2026 largely cover calendar 2026.

Full COO guide

Hinge Health is a digital musculoskeletal (MSK) care platform that provides physical therapy, pain management, and surgery prevention services through a combination of software, connected sensor hardware, and human care teams. The company's core offering combines a mobile and connected-sensor app with personalized exercise therapy programs, behavioral health support, and access to physical therapists, plus care navigation for surgery decisions. Customers are primarily large employers and health plans that purchase Hinge Health benefits for their members.

Full HNGE guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• COO drivers: Myopia management and premium lens mix; Activist pressure and a possible breakup.
• HNGE drivers: Employer benefit penetration; Surgery prevention as ROI driver.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Demand is the immediate problem: consumer weakness in Japan and China pushed CooperVision revenue in Asia-Pacific down ~6% earlier in the year, U.S. For HNGE, digital health categories are competitive with various platforms targeting MSK and other condition areas, including the well-funded private Sword Health.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick COO if you believe its drivers more; HNGE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the COO and HNGE guides.

COO. GAAP and non-GAAP still diverge sharply, now in both directions: the trailing GAAP figure absorbs the ~$271.6M litigation charge and years of acquisition amortization but also a ~$307.2M U.K. tax benefit. On adjusted EPS guidance of ~$4.51 to ~$4.55, the shares at ~$58 trade near 12-13x, well below the multiple Cooper carried through most of the last decade, and 15 analysts hold a hold rating with a mean target near ~$65.80. The fiscal year closes October 31, and fourth-quarter guidance is ~$1.057B to ~$1.080B of revenue and ~$1.05 to ~$1.09 of adjusted EPS.

HNGE. Hinge Health's valuation has moved from a story about reaching profitability to one about sustaining fast, profitable growth. At about 33x trailing and forward earnings and 11x sales after a ~123% year-to-date gain, the shares sit just below the ~$112 average analyst target, so the November 2 third-quarter report (consensus ~$0.60 EPS on ~$224.8 million of revenue) will be read for whether growth near 50% can hold.

Headline figures (approximate, October 2026): COO shows revenue (ttm) ~$4.24B; July quarter up ~0.6%, fiscal 2026 revenue guidance (september) ~$4.229B to ~$4.252B, fiscal 2026 adjusted eps guidance ~$4.51 to ~$4.55, forward p/e ~12x at ~$58 per share; HNGE shows revenue (ttm) ~$720 million; Q2 2026 ~$212.8 million, up ~53% year over year, gross / operating margin ~85% / ~19%, net income (ttm) ~$107 million (Q2 2026 ~$43.1 million), adjusted eps (q2 2026) ~$0.59 vs ~$0.62 estimate.

COO and HNGE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined COO and HNGE exposure against your real portfolio. It is not an investment adviser.